Simplex Trading’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-54,200
| Closed | -$1.28M | – | 10245 |
|
|
2023
Q4 | $1.28M | Sell |
54,200
-79,700
| -60% | -$1.42M | ﹤0.01% | 2780 |
|
|
2023
Q3 | $2M | Buy |
133,900
+133,800
| +133,800% | +$1.77M | ﹤0.01% | 2072 |
|
|
2023
Q2 | $1K | Sell |
100
-39,800
| -100% | -$371K | ﹤0.01% | 8784 |
|
|
2023
Q1 | $347K | Buy |
39,900
+24,700
| +163% | +$198K | ﹤0.01% | 3664 |
|
|
2022
Q4 | $95K | Sell |
15,200
-7,800
| -34% | -$29.6K | ﹤0.01% | 5153 |
|
|
2022
Q3 | $80K | Sell |
23,000
-100
| -0.4% | -$359 | ﹤0.01% | 5829 |
|
|
2022
Q2 | $68K | Buy |
23,100
+6,500
| +39% | +$15.5K | ﹤0.01% | 6083 |
|
|
2022
Q1 | $51K | Buy |
16,600
+11,600
| +232% | +$36.5K | ﹤0.01% | 7111 |
|
|
2021
Q4 | $16K | Sell |
5,000
-16,600
| -77% | -$63K | ﹤0.01% | 8637 |
|
|
2021
Q3 | $95K | Buy |
21,600
+2,500
| +13% | +$9.85K | ﹤0.01% | 6698 |
|
|
2021
Q2 | $83K | Buy |
19,100
+19,019
| +23,480% | +$84.3K | ﹤0.01% | 7002 |
|
|
2021
Q1 | $36K | Buy |
+81
| New | +$436 | ﹤0.01% | 6974 |
|
|
2019
Q4 | – | Sell |
-33
| Closed | -$16K | – | 8147 |
|
|
2019
Q3 | $16K | Sell |
33
-147
| -82% | -$890 | ﹤0.01% | 5978 |
|
|
2019
Q2 | $128K | Buy |
180
+95
| +112% | +$1.08K | ﹤0.01% | 3934 |
|
|
2019
Q1 | $112K | Sell |
85
-4
| -4% | -$43 | ﹤0.01% | 4220 |
|
|
2018
Q4 | $70K | Sell |
89
-33
| -27% | -$314 | ﹤0.01% | 4201 |
|
|
2018
Q3 | $135K | Buy |
122
+121
| +12,100% | +$1.5K | ﹤0.01% | 4105 |
|
|
2018
Q2 | $1K | Buy |
+1
| New | +$13 | ﹤0.01% | 7225 |
|
Other funds holding CBAY
Simplex Trading's CBAY Position: Q4 2023 in Review
Simplex Trading sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 55,629 shares — an estimated $991K sold.
Simplex Trading first reported a position in CBAY in Q3 2018 and held it in 14 quarters. The position peaked at $829K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.
- Simplex Trading reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
- Simplex Trading sold 55,629 Cymabay Therapeutics shares in Q4 2023, an estimated $991K.
- Simplex Trading first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 14 quarters.
- Simplex Trading's Cymabay Therapeutics position peaked at $829K in Q3 2023.
- 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.
Based on Simplex Trading's 13F filing for Q4 2023, filed 2 Feb 2024.